Abstract
Objectives The patient-reported Multiple Sclerosis Neuropsychological Questionnaire (MSNQ) is inconsistently related to objective cognitive tests in multiple sclerosis (MS), while being strongly correlated with depression. In this study we test whether the relation between subjective and objective cognitive performance is moderated by physical disability, assessed by the Expanded Disability Status Scale (EDSS).
Materials & Methods From 275 MS patients who completed the patient-report MSNQ and the two-question screening tool for depression, we collected Symbol Digit Modalities Test (SDMT) and EDSS scores, indicators of respectively objective cognitive performance and physical disability. We analysed correlations between these variables in the total group and in three EDSS subgroups: Low 0.0 – 3.0, Medium 3.5 – 6.0 and High 6.5 – 9.0. We also investigated the use of a composite measure of cognitive impairment and depression.
Results We found no significant correlations between patient-reported MSNQ and SDMT scores in the total group or the EDSS subgroups. MSNQ scores correlated significantly with depression in all subgroups. After correcting for several variables, MSNQ scores contributed adversely to SDMT scores in the total group, not in any subgroup. MSNQ scores contributed significantly to the prediction of the composite measure of impairment in the total group and in all EDSS subgroups.
Conclusions The relationship between measures of subjective and objective cognitive performance is not influenced by the patient’s level of physical disability. MSNQ scores are substantially influenced by depression, and reflect cognitive function to some degree. The patient-report MSNQ can be useful to identify patients requiring further (neuro)psychological assessment.
Competing Interest Statement
DVL declares no potential conflicts of interest. ADC declares no potential conflicts of interest. JVS declares no potential conflicts of interest. RHBB received honoraria, speaking, or consulting fees from Biogen, Celgene, EMD Serono, Genentech, Medday, Novartis, Roche, Sanofi, Genzyme and Verasci; research support from Biogen, Genentech, Novartis, NIH, National MS Society, Genzyme and Mallinkrodt; and royalties from Psychological Assessment Resources. GN declares no potential conflicts of interest. MBD received fees for consultancy and advisory boards of Roche, Biogen, Almirall and Novartis and restricted grants and/or congress support from Biogen, Roche and Novartis.
Clinical Trial
NA
Funding Statement
This research was funded by Biogen Fellowship Grant (ID #2016004-MS), which was provided by Biogen International GmbH to the National Multiple Sclerosis Center Melsbroek, Belgium (NMSC). Additional funding was provided by the MS Fonds KU Leuven.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethical committee at the University Hospital Brussels (B.U.N. 143201630261, 2016/357, 25 January 2017). Ethical committee at the National Multiple Sclerosis Center Melsbroek (17/02, 24 January 2017).
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
↵* Guy Nagels and Marie D’hooghe should be considered joint senior author.
Data Availability
Data is available upon reasonable request to the authors.
